Wednesday, August 26, 2015
Hybrigenics, a Paris-based biopharmaceutical company, has received Orphan Drug designation by the FDA for inecalcitol for the treatment of acute myeloid leukemia (AML) in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including tax credits for qualified clinical testing.
Celgene, headquartered in Summit, N.J., and Seattle-based Juno Therapeutics have formed a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.
AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin’s lymphoma, myelodysplastic syndromes and multiple myeloma.
Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.